[Prevalence of latent toxoplasma infection in HIV infection patients].
BACKGROUND
To know the prevalence of Toxoplasma gondii latent infection in HIV-1 infected patients and to compare it with the prevalence in a group of parenteral drug users, non-infected by HIV.


METHODS
We study 255 HIV-1 patients revised in our hospital in the last 6 years. The control group were 116 drug addicts non-infected by HIV followed in an educational program of deshabituation. We tested IgG anti-toxoplasma by enzymatic inmunoessay (MEIA). An IgG plasma value of 6UI/ML or more was an indicative of toxoplasma previous infection. We used Chi Square and Yatchts correction tests for the statistical analysis, settling down a significance point of 95%.


RESULTS
We founded 36.7% positive IgG anti-toxoplasma in the group on HIV-1 infected patients, non drugs addicts, against 30.9% in the group of HIV-1 drug addicts patients. (OR 0.77; 0.35 < OR < 1.66). The control group showed a Toxoplasma seroprevalence of 26.7%, without statistically significant against the drug addicts HIV group (OR = 1.55; 0.93 < OREGON < 2.59).


CONCLUSIONS
The seroprevalence of Toxoplasma gondii latent infection in our study was similar to the european results. We didn't found a higher prevalence in HIV-1 patients than in patients non infected by HIV-1.
Boto de los Bueis
A
A
Servicio de Medicina Interna, Hospital Juan Ramón Jiménez, Huelva.
Vega Alemán
D
D
Gálvez Acebal
J
J
Merino Muñoz
D
D
Creagh Cerquera
R
R
Pujol de la Llave
E
E
D000328:Adult; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000469:parasitology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D012698:Serologic Tests; D015819:Substance Abuse, Intravenous / Q000469:parasitology*; D014122:Toxoplasma / Q000276:immunology; D014123:Toxoplasmosis / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology*
D000913:Antibodies, Protozoan; D007074:Immunoglobulin G
Prevalencia de infección latente frente a toxoplasma en pacientes con infección VIH.